drugset / Trial / NCT05394285
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study now plans to explore the efficacy and safety of hetrombopag in cancer therapy-induced thrombocytopenia in advanced breast cancer, so as to further guide the clinical application of hetrombopag in chemotherapy-induced platelets.
Timeline
- Start
- 2022-09-21
- Primary completion
- 2025-06-25
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hetrombopag | Small molecule | 7.5 mg | Oral |